Search clinical trials for: Rufinamide (E2080)

Total 186 results

Eisai Limited

Completed

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

Lennox-Gastaut Syndrome

Japan
Eisai Co., Ltd.

Completed

A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

Lennox-Gastaut Syndrome

Japan
Eisai Inc.

Terminated

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Refractory Partial Onset Seizures

United States
Eisai Inc.

Completed

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

Epilepsy

United States
Zambon SpA

Completed

A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers

Healthy

China
Zambon SpA

Completed

Safinamide for Multiple System Atrophy (MSA)

Multiple System Atrophy

Italy, Spain
Zambon SpA

Withdrawn

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

Parkinson Disease | Dyskinesia, Drug-Induced
University of Zurich

Completed

Effect of Oral Rufinamide and Oxcarbazepine on Nerve Excitability, Hyperalgesia, Allodynia and Flare Reaction Compared to Placebo. A Monocenter, Randomized, Double-blind, Cross-over Study

Healthy Subjects

Switzerland
Alain Kaelin
Clinical Trial Unit Ente Ospedaliero Cantonale

Recruiting

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

Idiopathic Parkinson's Disease (at Later Stage)

Switzerland
Newron Pharmaceuticals SPA
Parexel; CliniRx

Completed

Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain

Pain

United Kingdom
Newron Pharmaceuticals SPA

Completed

Phase II Dose Titration Study in Patients With Neuropathic Pain

Neuropathic Pain

United Kingdom, Czech Republic, Poland, Italy, India, Austria
Wuhan Union Hospital, China

Completed

Pharmacokinetics and Tolerability of Rufinamide in Healthy Chinese Subjects

Seizures
Newron Pharmaceuticals SPA

Completed

Safinamide Renal Impairment Trial

Renal Impairment

Germany
Supernus Pharmaceuticals, Inc.

Completed

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) (PRO-Go)

Idiopathic Parkinson Disease

United States
Zambon SpA

Completed

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

Idiopathic Parkinson Disease

Spain, Austria, Italy, Germany, France
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

Parkinson's Disease
Newron Pharmaceuticals SPA

Terminated

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Parkinson's Disease

Romania
CerRx, Inc.

Unknown

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

Peripheral T-cell Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth

Head and Neck Cancer

United States
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

Hepatic Impairment

Germany
Eisai Inc.

Completed

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

Healthy Volunteers

United States
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Idiopathic Parkinson's Disease
Newron Pharmaceuticals SPA

Completed

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

Parkinson's Disease With Cognitive Impairments

Spain, United States
SciTech Development, LLC
Rush University Medical Center

Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Mycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditions

United States
Newron Pharmaceuticals SPA

Terminated

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Parkinson Disease

United States
Zambon SpA

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

Parkinson Disease

China
Newron Pharmaceuticals SPA

Completed

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

Parkinson's Disease
IRCCS San Raffaele Roma

Completed

Overnight Switch From Rasagiline To Safinamide (SWH-MAOB)

Parkinson Disease

Italy
Newron Pharmaceuticals SPA

Completed

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects (Safinamide-LID)

Parkinson's Disease

Austria, Canada, France, Germany, South Africa
Newron Pharmaceuticals SPA

Completed

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

Parkinson's Disease
Eisai Inc.

Available

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Lennox Gastaut Syndrome

Poland
Eisai Korea Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Parkinson Disease

Korea, Republic of
Newron Pharmaceuticals SPA

Terminated

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) (MOTION)

Idiopathic Parkinson's Disease

Switzerland
Eisai Co., Ltd.

Completed

Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome

Japan
Eisai Inc.

Terminated

A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy

Photosensitive Epilepsy

United States
Eisai Co., Ltd.

Terminated

Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects

Healthy Participants

Japan
Biotie Therapies Inc.
Syneos Health

Completed

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder

United States
University of South Alabama

Withdrawn

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

Refractory Partial Seizures

United States
Emory University
National Cancer Institute (NCI); Eisai Co., Ltd.

Recruiting

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Unresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC... and other conditions

United States
Eisai Inc.

Completed

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

Lennox-Gastaut Syndrome

France, Poland, United States, South Africa, Italy, Canada, Greece
Emory University
Eisai Inc.

Terminated

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States
University of Zurich

Withdrawn

Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome (RUFPTPS)

Pain | Peripheral Nerve Injuries

Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

Breast Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Metastatic Adrenal Gland Pheochromocytoma | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma

United States
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | Recurrent High Grade Fallopian Tube Serous Adenocarcinoma | Recurrent High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma | Peritoneal High Grade...

United States
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8

United States
Eisai Co., Ltd.

Completed

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

Japan, Korea, Republic of
Eisai Inc.

Completed

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Hepatic Impairment | Hepatic Function

United States
Humanity & Health Medical Group Limited
Beijing 302 Hospital; Kindai University Faculty of Medicine

Terminated

Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors

Hepatocellular Carcinoma

Hong Kong

Search clinical trials for: Rufinamide (E2080)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations